Piperidin-4-ol → HCID 59592911, compound

HRID 2098630Notes

Reaction equation

HRID 2098630 reaction equation
[NH:1]1[C:9]2[C:4](=[C:5]([C:10]3[N:11]=[C:12]([N:22]4[CH2:27][CH2:26][O:25][CH2:24][CH2:23]4)[C:13]4[CH:18]=[C:17]([C:19]([OH:21])=O)[S:16][C:14]=4[N:15]=3)[CH:6]=[CH:7][CH:8]=2)[CH:3]=[N:2]1.[NH:28]1[CH2:33][CH2:32][CH:31]([OH:34])[CH2:30][CH2:29]1>>[NH:1]1[C:9]2[C:4](=[C:5]([C:10]3[N:11]=[C:12]([N:22]4[CH2:23][CH2:24][O:25][CH2:26][CH2:27]4)[C:13]4[CH:18]=[C:17]([C:19]([N:28]5[CH2:33][CH2:32][CH:31]([OH:34])[CH2:30][CH2:29]5)=[O:21])[S:16][C:14]=4[N:15]=3)[CH:6]=[CH:7][CH:8]=2)[CH:3]=[N:2]1

Participants

3

Reactant 2

HCID 79341Piperidin-4-olHCID 595928852-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidine-6-carboxylic acid

Product 1

HCID 59592911HCID 59592911, compound

Procedure

45 mg of 2-(1H-indazol-4-yl)-4-morpholinothieno[2,3-d]pyrimidine-6-carboxylic acid 14 was coupled to piperidin-4-ol via General Procedure B. The product was purified via reverse phase HPLC to give 46.6 mg of 123 MS (Q1) 465.1 (M)+.

Workup

  1. customThe product was purified via reverse phase HPLC

Sources & evidence

ORD record
ord-5bb01b01f90346e6a6711f8ad244a7e5
Source dataset
uspto-grants-2013_05
Patent number
US08450315B2

Reaction notes

Loading…